This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Chris Vlahos
Global Head, Rare Disease External Innovation at Ipsen


Chris J. Vlahos, PhD joined Ipsen in November 2018 as Global Head of Rare Disease and Neuroscience External Innovation (EI). Chris leads EI efforts to identify and evaluate innovative external opportunities in Rare Disease and Neuroscience, as well as the development and implementation of an External Innovation strategy in these areas. Chris has more than 30 years of experience in pharmaceutical research across a broad range of therapeutic areas including 10 years in external innovation and due diligence. Chris started his career at Lilly Research Laboratories in 1986 where he held various positions of increasing responsibilities in Cardiovascular Discovery Research. In 2008, he was named Director, External Innovation-Endocrine where he was responsible for identification, and scientific and technical evaluation of in-licensing and M&A opportunities in multiple therapeutic areas. Prior to joining Ipsen, Chris provided independent consultation on preclinical drug discovery, development and strategy, due diligence and business development in diverse therapeutic areas. Chris holds a BS (cum laude) in Chemistry from Santa Clara University, and a Master of Science and a Ph.D., both in Biological Chemistry from the University of Michigan.

Agenda Sessions

  • Rare and orphan diseases: The value proposition of new modalities vs established ones - Hilton Union Square